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 Small sample size 
 Difficult to draw conclusions based on comparative data between 
patients with defined and undefined allergies 
 Unable to determine cost savings with use of alternative antibiotics
 Documentation in the EHR was not complete/thorough 
 Information from outside of hospital stay not easily accessible 
 Time frame for defined allergies (i.e. anaphylaxis)
 Prior medication use (i.e. AHs) 
 Resolution of infection for patients discharged on outpatient 
antibiotics 
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CONCLUSION
 Aztreonam and levofloxacin were the most common non-BL 
antibiotics prescribed for patients with a reported PCN allergy
 Majority (68%) of reported PCN allergies were undefined
 The most common infection types were urinary tract infections (UTI), 
community-acquired pneumonia (CAP) and hospital-acquired 
pneumonia (HAP)
 Infectious diseases (ID) physicians were more likely to prescribe 
cephalosporins 
 Hospitalists were more likely to prescribe fluoroquinolones
RESULTS
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BACKGROUND
 Penicillin (PCN) is the most commonly reported beta-lactam (BL) 
allergy; prevalence among hospitalized patients is ~10%–20%1
 Less than 10% of these patients are truly allergic, but common side 
effects of BLs (i.e. fever, nausea, vomiting, diarrhea) are often 
mistaken for allergic reactions and inaccurately documented as an 
allergy in the electronic health record (EHR)1,2
 A true PCN allergy may decrease over time; 50% of patients lose 
sensitivity after 5 years and 80% after 10 years3
 Patients with a reported PCN allergy are often treated with non-BL 
broad-spectrum antibiotics3,4, which may lead to suboptimal 
antibiotic therapy, more adverse events, development of multi-drug 
resistant infections, increased length of stay, ICU admissions, higher 
mortality and increased treatment costs5,6
 Cross reactivity reported for 1st generation cephalosporins is ~ 1% 
and negligible for 2nd generation cephalosporins yet all 
cephalosporins are often avoided in patients with a reported PCN 
allergy7
OBJECTIVES
 Determine the incidence, clinical outcomes and costs associated 
with the use of alternative antibiotic treatment in patients with a 
reported PCN allergy
 Establish the foundation for a follow-up phase II study evaluating 
the impact of a pharmacy-driven PCN allergy assessment on allergy 
clarification and antibiotic selection
METHODS
 Study design: Single-center, retrospective chart review of patients 
admitted to Baptist Hospital of Miami with a reported PCN allergy 
between February 1, 2018 and August 1, 2018
 Inclusion criteria: Individuals ≥ 18 years old, reported PCN allergy, 
diagnosis of an infection for which a PCN or a BL antibiotic can be 
used, received antibiotics for at least one day during hospital stay 
 Exclusion criteria*: Patients receiving antihistamines (AH)- 1st 
generation AH within 24 hours, or a 2nd generation AH within the 5 
days prior to antibiotic administration, severe immunosuppression 
(i.e. HIV with CD4 count <200 cells/µL, neutropenia, malignancy, 
transplant patients taking immunosuppressive medications), 
anaphylactic allergy to PCN within the last 10 years, 
pregnant/breastfeeding, severe cardiovascular or pulmonary 
comorbidities
 Primary outcomes: Type of antibiotic(s) used, costs, adverse effects 
and allergy documentation 
 Secondary outcomes: Length of stay, duration of therapy, resolution 
of infection and mortality 
 Reported allergies were reviewed and categorized into one of two 
categories:
 Defined: both an allergy to PCN and the associated reaction are 
documented on the EHR
 Undefined: an allergy to PCN is documented on the EHR without 
an associated reaction 
* Exclusion criteria reflects that which will be used for phase II of this study in which patients may be eligible 
for PCN skin testing and was designed in an effort to increase patient safety
DISCUSSION
 Inaccurate allergy documentation may lead to unnecessary use of 
non-BL broad-spectrum antibiotics and higher treatment costs
 Accurate allergy documentation by healthcare providers (i.e. nurses, 
pharmacists) and thorough review of allergy documentation by 
prescribers can potentially minimize unnecessary antibiotic use and 
decrease overall treatment costs
 Prospective studies should be conducted to assess the impact of a 
pharmacy-driven PCN allergy assessment (detailed patient interview) 
in an attempt to clarify/define allergy history
Adverse Effects n Antibiotic
Anxiety 1 Levofloxacin






















































ANTIBIOTIC SELECTION PER INFECTION TYPE















Note: Data reflects total number of antibiotics used in 50 patients 
Secondary Outcomes n=50
Mean length of stay (days) 10.5
Mean duration of therapy (days) 5.6
Mortality, n (%)
Cardiopulmonary arrest 2 (1%)







Prescribing Trends by Specialty
Prescriber Aztreonam Levofloxacin Cephalosporins
ID 10 4 8
Hospitalist 5 11 3
Critical care 1 0 0
Pulmonologist 1 1 1
Nephrologist 1 1 0
Gastroenterologist 0 1 0
Internal Medicine 0 0 1
Antibiotic Cost
Aztreonam $ 12,080.64 
Tigecycline $ 2,253.60 
Levofloxacin $ 2,134.20 
Doxycycline $ 1,743.20 
Ertapenem $ 1,543.90 
Cefepime $ 1,409.36 
Clindamycin $ 922.72 
Vancomycin $ 680.70 
Meropenem $ 633.60 
Ceftriaxone $ 264.48 
Metronidazole $ 115.32 
Cefuroxime $ 48.00 
Azithromycin $ 28.80 
Cephalexin $16.56
Total Cost: $23,875.08
(All costs calculated using average wholesale price)
Baseline Characteristics n=50
Mean age (years) 72
Gender, n (%)
Female 33 (66%)
Dual antibiotic therapy, n (%) 21 (42%)
Infection Type, n (%):
UTI
CAP
HAP
SSTI
Intra-abdominal infection
Aspiration pneumonia
Sepsis 
Gynecologic infection
Acute sinusitis
16 (30%)
9 (18%)
7 (14%)
6 (12%)
5 (10%)
3 (6%)
2 (4%)
1 (2%)
1 (2%)
34
(68%)
16
(32%)
Allergy Documentation
Undefined Defined
